Company* |
University/ |
Type Of Agreement | Product Area |
Details (Date) |
| | ||||
Acambis plc (UK; ACAM) |
World Health Organization |
Collaboration |
Acambis' vaccine, ChimeriVax- E, against Japanese encephalitis |
WHO will provide assistance and funding for pediatric trials of the vaccine in endemic countries (11/25) |
|
|
|
|
|
Advanced Bio/Chem Inc. (OTC BB:AVBC) |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Deal covering diagnosis and monitoring of breast cancer through proteomic analysis of breast ductal fluids |
The company licensed rights to the technology on which the two parties have been collaborating (3/15) |
|
|
|
|
|
Affymetrix Inc. (AFFX) |
Translational Genomics Research Institute |
Agreement |
TGen will offer geno- typing services to collaborators and NIH programs using Affymetrix technology |
The nonexclusive license is for work covering DNA analysis technology; they also began planning future collaborations (2/11) |
|
|
|
|
|
Alnylam Pharmaceuticals Inc.* |
Cold Spring Harbor Laboratory |
License agreement |
Alnylam licensed technology related to the induction of gene silencing in mammalian cells through RNAi |
The license is nonexclusive and covers therapeutic uses of the patent; terms were not disclosed (1/22) |
|
|
|
|
|
Alteris Therapeutics Inc.* |
Duke University and Johns Hopkins University |
License agreement |
Alteris licensed additional rights to a vaccine (ALT-110) targeting EGFR variant 3 |
Both universities took an equity stake in Alteris as part of the deal; previous rights were licensed from Thomas Jefferson University (2/18) |
|
|
|
|
|
Angiotech Pharmaceuticals Inc. (Canada; ANPI) |
University of British Columbia (Canada) |
License agreement |
Angiotech licensed technologies on drug- loaded medical devices and biomaterials |
Included in the deal is a jointly developed stent endograft program designed to treat abdominal aortic aneurysms; terms were not disclosed (3/17) |
|
|
|
|
|
Aphios Corp.* |
National Cancer Institute | Material transfer agreement |
Deal to access natural products repository of terrestrial plants and marine organisms |
Terms of the deal were not disclosed (3/16) |
|
|
|
|
|
Ariana Pharmaceuticals* (France) |
Centre National de Recherche Scientifique (France) |
Collaboration extension |
Exclusive access to use artificial intelligence technology developed by Ariana and a CNRS lab |
The collaboration focuses on further developing the technology to improve the prediction of the quality profile of molecules (12/15) |
|
|
|
|
|
Aton Pharma Inc.* |
National Cancer Institute |
Clinical trials agreement |
Development of Aton's SAHA in single-agent and combination trials |
The deal with the NCI's Cancer Therapy Evaluation Program will support development of the drug (11/20) |
|
|
|
|
|
Avigen Inc. (AVGN) |
University of Colorado |
License deal |
Treating chronic pain through use of anti- inflammatory cytokines, including IL-10 |
Avigen gained exclusive rights to patent applications covering the technology; it also expanded its sponsored research agreement with CU-Boulder on research in chronic pain (12/8) |
|
|
|
|
|
Benitec Ltd. (Australia; ASX:BLT) |
Commonwealth Scientific and Industrial Research Organisation (Australia) |
License resolution |
DNA-directed RNA interference |
Agreement resolves dispute on technology among Benitec, CSIRO and the Queensland Department of Primary Industries, allowing all to pursue their fields of interest (12/8) |
|
|
|
|
|
BioMosaics Inc.* |
Sunnybrook and Women's College Health Sciences Centre (Canada) |
License deal |
A diagnostic test for primary liver cancer that uses a monoclonal antibody to glypican 3 |
BioMosaics licensed worldwide exclusive rights to the test for detecting liver cancer (11/25) |
|
|
|
|
|
Binomics Ltd. (Australia; ASX:BNO) |
Walter and Eliza Hall Institute (Australia) |
Collaboration |
Parties signed letter of intent to collaborate on work in ion channels |
The focus of the deal will be to identify new lead molecules for treating central nervous system disorders (2/24) |
|
|
|
|
|
Bruker Daltonics Inc. (unit of Bruker BioSciences Corp.; BRKR) |
Leiden University Medical Center (the Netherlands) |
Research collaboration |
The center acquired mass spectrometry systems from Bruker |
The center will provide feedback for clinical research applications; terms were not disclosed (12/4) |
|
|
|
|
|
Celmed BioSciences Inc. (subsidiary of Theratechnologies Inc.; Canada; TSE:TH) |
National Heart, Blood and Lung Institute |
Collaboration agreement |
Preclinical research using Celmed's photo-dynamic Theralux device |
They will test the device for use in graft-vs.-host disease; the plan is to move into a Phase I/II trial after developing and optimizing the methodology (12/10) |
|
|
|
|
|
Cerus Corp. (CERS) |
Johns Hopkins University |
License agreement |
Cerus acquired certain exclusive rights to the cancer antigen mesothelin |
Johns Hopkins gets an up- front payment and would get royalties on sales and revenues from sub-licensing deals; the antigen has applicability in pancreatic and ovarian cancers (1/28) |
|
|
|
|
|
Cetek Corp.* |
M.D. Anderson Cancer Center |
Collaboration |
To discover and develop drugs targeting cancer and inflammatory diseases |
Cetek will use its natural product technologies to isolate drug-like compounds; details were not disclosed (1/7) |
|
|
|
|
|
ChondroGene Ltd. (Canada; TSE:YDG) |
Canadian Arthritis Network |
Research collaboration |
ChondroGene will make its technology available to network researchers and gain access to their research activity |
Projects will be identified, with the goal to advance Chondro-Gene's research and develop diagnostics for osteoarthritis, and then therapeutics (12/2) |
|
|
|
|
|
Chronogen Inc.* (Canada) |
McGill University (Canada) |
License agreement |
Screening assays for targets and drugs useful in treating lipid disorders linked to atherosclerosis |
Chronogen licensed worldwide rights to the technology; the parties also concluded a research collaboration to develop pre-clinical models, to which Chronogen has exclusive rights (12/10) |
|
|
|
|
|
CombiMatrix Group (CMBX; unit of Acacia as Research Corp.) |
St. Jude Children's Research Hospital |
Collaboration |
To study the genetic variation in the H9 variant of influenza A (bird flu) |
The collaboration will investigate the use of chip- based, whole-genome screening of virus strains a tool to monitor the emergence of new strains (3/17) |
|
|
|
|
|
CombiMatrix Group (CMBX; unit of Acacia Research Corp.) |
Case Western Reserve University |
Collaboration |
To develop a diagnostic for Alzheimer's disease |
The work will use the CombiMatrix CustomArray platform; terms of the collaboration were not disclosed (2/23) |
|
|
|
|
|
CombiMatrix Group (CMBX; unit of Acacia Research Corp.) |
Washington University |
Collaboration |
To develop a system for the synthesis of libraries of diverse, non-nucleic acid molecules |
The libraries will be synthesized using CombiMatrix technology; the university is doing the work under a grant from the National Science Foundation (1/20) |
|
|
|
|
|
Competitive Technologies Inc. (AMEX:CTT) |
University of South Carolina Research Foundation |
Exclusive agreement |
CTI licensed a small- molecule angiogenesis inhibitor with applications in cancer |
Terms of the deal were not disclosed (2/24) |
|
|
|
|
|
CytoGenix Inc. (OTC BB:CYGX) |
Baylor College of Medicine |
Collaboration |
Deal for preclinical testing of a product for lung cancer |
The work will combine the company's ssDNA expression vectors and Baylor's aerosol gene delivery technology against a metastasis gene; terms were not disclosed (1/21) |
|
|
|
|
|
CytoGenix Inc. (OTC BB:CYGX) |
Louisiana State University |
Research agreement |
Deal for preclinical work on a gene shown to cause malignant transformation of tumor cells |
The work will use the company's ssDNA expression vector technology to silence the gene; terms of the deal with the university's Health Sciences Center were not disclosed (3/15) |
|
|
|
|
|
CytoGenix Inc. (OTC BB:CYGX) |
University of exas Health Science Center |
Agreement for studies |
The company's ssDNA technology against a gene to inhibit bacterial reproduction |
The university's Houston Medical School will conduct preclinical tests on sepsis in mice (12/15) |
|
|
|
|
|
CytRx Corp. (CYTR) |
University of Massachusetts Medical School |
Collaboration |
CytRx will fund work at UMMS on gene- silencing technologies for treating cyto-megalovirus diseases |
The deal is an expansion of their collaboration; CytRx gets worldwide commcerial rights to resulting discoveries (1/13) |
|
|
|
|
|
Dharmacon Inc.* |
University of Massachusetts Medical School |
Collaboration |
To use RNA interference to study obesity and diabetes |
Dharmacon will design and supply siRNA reagents for UMMS studies on gene targets; terms of the three- ear effort were not disclosed (1/8) |
|
|
|
|
|
EntreMed Inc. (ENMD) |
Children's Medical Center Corp. |
License deal |
EntreMed transferred to CMCC the rights to the endostatin and angiostatin programs outside of Asia |
Alchemgen Therapeutics Inc. got rights in Asia; EntreMed gets upfront payments and would get 20% of any proceeds CMCC derives from the products (1/4) |
|
|
|
|
|
Genaera Corp. (GENR) |
Ludwig Institute for Cancer Research (Germany) |
Collaboration |
Two-year extension on deal to discover and develop genes and proteins |
The focus is on finding pharmaceutical targets and therapeutics, and includes work on interleukin-9; terms were not disclosed (3/8) |
|
|
|
|
|
Genaissance Pharmaceuticals Inc. (GNSC) |
Tokyo Women's Medical Center (Japan) |
Purchase agreement |
HAP typing services for use in a study on drug response |
Genassiance will provide the services; terms were not disclosed (12/4) |
|
|
|
|
|
Genedata AG* (Switzerland) |
University of Minnesota |
Collaboration |
Extension of license to Genedata's Expressionist, a computational system for large-scale gene expression analysis |
The university's Supercomputing Institute for Digital Simulation and Advanced Computation is using the technology in multiple areas (12/2) |
|
|
|
|
|
GeneMax Corp. (Canada; OTC BB: GMXX) |
The University of British Columbia (Canada) |
License agreement |
GeneMax got an exclusive worldwide license to an assay technology used for drugs that regulate immune responses |
GeneMax subsidiary GeneMax Pharmaceuticals Inc. got the license; terms were not disclosed (2/19) |
|
|
|
|
|
Genencor International Inc. (GCOR) |
U.S. Army Edgewood Chemical Biological Center |
License agreement |
For enzymes to decon- taminate certain organo-phosphateased nerve agents, such as sarin |
Genencor's license includes exclusive rights to commercialize the technology for all applications (2/19) |
|
|
|
|
|
Generex Biotechnology Corp. (GNBT) |
Chinese Academy of Science |
Collaboration |
To develop a SARS vaccine |
The effort will combine work at the academy with Generex's Antigen Express technology for enhancing vaccine potency; terms were not disclosed (2/23) |
|
|
|
|
|
GenMab A/S (Denmark; CSE:GEN) |
Sanquin Blood Supply Foundation (the Netherlands) |
Research collaboration |
To develop an improved treatment for hemophilia patients who don't respond to Factor VIII |
GenMab will support a research program at Sanquin to validate the approach, and has an option to license the technology (12/16) |
|
|
|
|
|
GenOhm Sciences Inc.* |
University of Rochester |
License agreement |
GenOhm licensed nucleic acid synthesis and amplification technology |
The coexclusive license will be used to develop diagnostic assays for identification of gene sequences (2/13) |
GenoMed Inc.* |
National Institute of Allergy and Infectious Diseases |
Agreement |
To test the company's compounds in tissue culture assays |
The NIAID will test compounds to evaluate activity against influenza, West Nile virus and SARS (12/18) |
|
|
|
|
|
GMP Companies Inc.* |
University of Michigan |
License and sponsored research agreement |
Class of compounds designed to treat auto- immune diseases and some forms of cancer |
GMP licensed the cytotoxic benzodiazepine compounds and will provide UM research funding, license fees, preclinical milestones and sales royalties (12/11) |
|
|
|
|
|
Health Discovery Corp. (OTC BB:HDVY) |
University of Texas M.D. Anderson Cancer Center |
Discovery agreement |
Biomarkers and path- ways in prostate cancer |
The company was granted first option to a worldwide, royalty-bearing license to products discovered using the company's technology (1/26) |
|
|
|
|
|
HemispherX Biopharma Inc. (AMEX:HEB) |
New York Hospital |
Clinical program |
To conduct a clinical program for West Nile virus |
The program will include testing Alferon N injection for the virus; the hospital will seek government support for testing (1/20) |
|
|
|
|
|
HemispherX Biopharma Inc. (AMEX:HEB) |
Vanderbilt University |
Clinical program |
To conduct a clinical program on SARS |
The program includes testing Alferon N injection for the virus; the university will seek government support for testing (1/13) |
|
|
|
|
|
Hudson Health Sciences Inc.* |
Yale University and the State University of New York |
License agreement |
Hudson licensed IPdR, a radiosensitizer being developed for brain cancer |
Details of the deal were not disclosed; Hudson expects to begin Phase I trials in 2004 (3/1) |
|
|
|
|
|
Immtech International Inc. (AMEX:IMM) |
University of North Carolina and Medicines for Malaria Venture (Switzerland) |
Development partnership |
Agreement to launch trials of malaria drug DB289 in Africa, Asia and South America |
Immtech will carry out clinical development work, UNC will provide research support and MMV will provide oversight and funding (12/3) |
|
|
|
|
|
Insmed Inc. (INSM) |
University of Rochester School of Medicine |
Collaboration |
To test Insmed's SomatoKine for treating myotonic dystrophy, a type of adult muscular dystrophy |
The university will get up to $5M from the National Institutes of Health and up to $1.5M from the Muscular Dystrophy Association to research therapies (1/7) |
|
|
|
|
|
Ingenium Pharmaceuticals AG* (Germany) |
Max Plank Institute (Germany) |
Agreement |
Ingenium will provide genetic mouse models to the institute |
The models were developed with Ingenium's Ingenotyping platform; details were not disclosed (12/19) |
|
|
|
|
|
Ingenium Pharmaceuticals AG* (Germany) |
German National Research Center for Environment and Health GmbH |
Agreement |
For Ingenium to access an additional murine tissue archive |
The deal is the second licensing agreement between the parties; details were not disclosed (12/19) |
|
|
|
|
|
Inovio A/S* (Norway) |
Navy Medical Research Center |
Cooperative Research and Development Agreement |
To evaluate Inovio's electroporation technology for delivery of Navy DNA vaccines |
The work will start with experiments in large animal models; details were not disclosed (12/30) |
|
|
|
|
|
Integrated BioPharma Inc. (AMEX:INB) |
Fraunhofer USA Inc.'s Center for Molecular Biotechnology |
License agreement |
Integrated acquired exclusive rights to technology for producing and testing human therapeutic proteins in plants |
Integrated will pay up-front and potential royalties on resulting products in exchange for broad rights to the intellectual property (1/13) |
|
|
|
|
|
Integrated BioPharma Inc. (AMEX:INB) |
The Institute for Cancer Prevention Inc. |
Collaboration |
To jointly research, develop and test compounds for anti- carcinogenic activity |
Integrated has exclusive rights to resulting discoveries and would pay the institute royalties on sales; the initial focus is on selenium compounds (1/6) |
|
|
|
|
|
Kemin Pharma (subsidiary of Kemin Industries Inc.; Belgium) |
U.S. Army Medical Research Institute for Infectious Diseases |
Collaboration |
To screen Kemin's library of carbohydrate- based small molecules against SARS and smallpox |
Terms of the deal were not disclosed (12/8) |
|
|
|
|
|
Keryx Biopharmaceuticals Inc. (KERX) |
Four universities |
Access agreement |
KRX-101 (sulodexide) in the treatment of various diseases |
Researchers from Vanderbilt University, the University of British Columbia, Baylor College of Medicine and Thomas Jefferson University will study the drug under Keryx's open-access program (3/9) |
|
|
|
|
|
Keryx Biopharmaceuticals Inc. (KERX) |
University of Michigan |
Access agreement |
KRX-101 (sulodexide) in the treatment of cardiovascular injury |
University researchers will assess the oral heparinoid compound's therapeutic potential in myocardial damage (11/25) |
|
|
|
|
|
LION Bioscience AG (Germany; LEON) |
European Bioinformatics Institute |
Expansion of relationship |
LION is letting the EBI and other academic institutions use its SRS software technology |
The institutions can use the SRS without restrictions; the deal also includes joint research efforts in bioinformatics (3/17) |
|
|
|
|
|
LION Bioscience AG (Germany; LEON) and DigiGenomics Co. Ltd.* |
Wan Fang Municipal Hospital of Taipei (Taiwan) |
Development agreement |
Deal to develop a SARS Knowledge Management System in Taiwan |
They will use LION's SRS relational module in the effort; terms were not disclosed (3/10) |
|
|
|
|
|
Metabolon Inc.* |
Massachusetts General Hospital and the University of Pittsburgh School of Medicine |
Collaboration |
Parties will study biomarkers and therapeutic targets for amyotrophic lateral sclerosis |
The work is being funded by the ALS Association; funding is for one year and could be renewed following release of initial data (2/12) |
|
|
|
|
|
Microscience Ltd.* (UK) |
U.S. Naval Medical Research Center |
Cooperative Research and Development Agreement |
Preclinical evaluation of a Microscience oral vaccine for anthrax |
Microscience will provide its spi-VEC delivery system for evaluation against NMRC models of efficacy; terms were not disclosed (12/8) |
|
|
|
|
|
Molecula Research Laboratories LLC (subsidiary of CalbaTech. Inc.; OTC BB: CLBE) |
Carnegie Institution |
Nonexclusive license |
Molecula got rights to U.S. Patent No. 6,506,599 on genetic inhibition by double-stranded RNA |
Molecula said the rights allow it to compete in the RNAi market; terms were not disclosed (12/15) |
|
|
|
|
|
Morphotek Inc.* |
National Cancer Institute |
Cooperative Research and Development Agreement |
To develop therapeutic antibodies to a cancer- associated protein identified at the NCI |
Morphotek will apply its Morphodoma antibody technology and the NCI will evaluate the antibodies in various solid tumors; terms were not disclosed (1/12) |
|
|
|
|
|
MWG Biotech AG* (Germany) |
Alimentary Pharmabiotic Centre (Ireland) |
Supply and services agreement |
MWG will support the creation of a micro- array facility at APC |
APC at the University of Cork will order a range of products and services; terms were not disclosed (12/4) |
|
|
|
|
|
Nastech Pharmaceutical Co. Inc. (NSTK) |
Carnegie Institute |
License agreement |
Nastech got a nonexclusive license to the Fire and related patents |
Nastech plans to use the siRNA technology in drug research and development; terms were not disclosed (2/2) |
|
|
|
|
|
Neurochem Inc. (Canada; NRMX) |
Institute for Biological Sciences (Canada) |
Agreement |
Neurochem is working with the institute's National Research Council on conjugated vaccines |
The focus is on Alzheimer's disease; Neurochem would own resulting products; terms were not disclosed (1/20) |
|
|
|
|
|
NitroMed Inc. (NTMD) |
Universities of Edinburgh and St. Andrews (UK) |
License agreement |
For R&D of NitroMed's nitric oxide-donor drugs for treating acute renal failure |
NitroMed has a right of first refusal to commercialize resulting discoveries; the deal was made in conjunction with the Wellcome Trust (2/9) |
|
|
|
|
|
NitroMed Inc. (NTMD) |
Boston University Schoolof Medicine |
Research collaboration |
To support basic research into clinical and pharmacologic roles of nitric oxide |
To support the program, NitroMed is opening a research facility in BU's BioSquare; terms were not disclosed (12/15) |
|
|
|
|
|
Norak Biosciences Inc.* |
National Cancer Institute |
Research evaluation agreement |
Deal to allow the NCI to evaluate Norak's Transfluor technology to screen GPCR cancer targets |
Terms of the deal were not disclosed (1/6) |
|
|
|
|
|
Onyvax Ltd. (UK) |
The Mayo Clinic |
License agreement |
Onyvax got rights to develop a vaccine for ovarian cancer |
Terms of the exclusive, world- wide license were not disclosed (1/15) |
|
|
|
|
|
Oxford BioMedica plc (UK; LSE:OXB) |
The Foundation Fighting Blindness |
Development support |
Preclinical studies of the company's vision-loss product RetinoStat |
The foundation will fund proof- of-principle studies using the LentiVector gene delivery system (11/27) |
|
|
|
|
|
Panacea Pharmaceuticals Inc.* |
Walter Reed Army Institute of Research |
Collaborative Research and Development Agreement |
They will evaluate PAN-811 and its deriv- atives as neuropro- tectants for global and focal ischemia |
Panacea will work with the institute's Division of Neurosciences, Department of Neuropharmacology and Molecular Biology; terms were not disclosed (3/17) |
|
|
|
|
|
Pharmetix Corp.* |
University of Glasgow (UK) |
Company formation |
Parties collaborated to form a new company, Grannus BioSciences Ltd. |
They will develop an anti-inflammatory, thymosin beta 4 sulphoxide, which was discovered at the university (2/12) |
|
|
|
|
|
Plantacor Inc.* |
Texas A&M University |
License agreement |
License to technology related to substituted diindolymethane ana- logues from cruciferous vegetables |
Plantacor got an exclusive license to develop resulting products for treating cancers and other diseases; terms were not disclosed (1/21) |
|
|
|
|
|
Praecis Pharmaceuticals Inc. (PRCS) |
National Cancer Institute |
Clinical trials agreement |
PPI-2458, a methionine aminopeptidase type-2 inhibitor |
They will work to develop a plan for clinical trials in various cancers; the drug is in a Phase I trial in non-Hodgkin's lymphoma (12/10) |
|
|
|
|
|
Prolexys Pharmaceuticals Inc.* |
Whitehead Institute for Biomedical Research |
Research collaboration |
Use of Prolexys' HySpec platform to investigate interactions between small molecules and proteins |
The two-year deal calls for proteomic analysis by Prolexys of compounds at the institute for cancer applications; terms were not disclosed (12/5) |
|
|
|
|
|
ProSkelia SAS* (France) |
German Cancer Research Center |
License agreement |
ProSkelia licensed technology related to signaling pathways involving Kremen and DKK |
The license covers use in bone diseases; the center gets R&D funding as well as potential mile- stones and royalties (3/3)** |
|
|
|
|
|
Proteome Sciences plc (UK; LSE:PRM) disease and vCJD |
UK Medical Research Council |
Collaboration |
To identify differential protein expression in Creutzfeld-Jacobs |
The goal is to develop diagnostics and treatments (11/26)** |
|
|
|
|
|
Protiveris Inc.* |
University of Tennessee- Battelle |
License deal |
Worldwide rights to sensor technologies |
Protiveris acquired rights and will apply the technology to micro- cantilever measurements of bio- molecular interactions (12/3) |
|
|
|
|
|
ProtoKinetix Inc. (Canada; OTC BB:PKTX) |
University of Michigan |
Exclusive option agreement |
The option is for development of drugs for breast cancer based on mammastatin |
Specific terms of the deal were not disclosed (2/2) |
|
|
|
|
|
Ricerca Biosciences LLC* |
Cleveland Clinic |
Collaboration |
Initial development of a drug therapy that uses cobalamin (vitamin B12) to carry a cancer drug |
They plan to take the product to the IND stage, then license it out for further development and marketing (1/26) |
|
|
|
|
|
Samaritan Pharmaceuticals Inc. (OTB BB:SPHC) |
Georgetown University |
License agremeent |
Parties finalized deal on university's patents related to modulating serum cortisol levels |
Samaritan said second- eneration compounds hold promise in a number of disease areas; terms were not disclosed (3/11) |
|
|
|
|
|
Samaritan Pharmaceuticals Inc. (OTB BB:SPHC) |
Georgetown University |
Collaboration expansion |
Expanding development scope in core areas of AIDS, Alzheimer's, cancer and cardiovascular diseases |
Samaritan is increasing its funding and continues to have first right of refusal to exclusively license the results; the deal was extended five years to 2013 (2/9) |
|
|
|
|
|
Sequenom Inc. (SQNM) |
Health Protection Agency (UK) |
Collaboration |
To apply Sequenom's MassArray technology in the genetic identification and differentiation of microbes |
The goal is to develop genetic markers that differentiate pathogenic from nonpathogenic strains of the microbes; terms were not disclosed (1/22) |
|
|
|
|
|
Sidec Technologies AB* (Sweden) |
University of Alabama at Birmingham |
Collaboration |
To provide a solution for structure-based drug design |
Sidec and UAB's Center for Biophysical Sciences and Engineering will co-market services that pair their technologies (12/12) |
|
|
|
|
|
Sinovac Biotech Ltd. (China; OTC BB: SNVBF) |
Center for Disease Control of China |
Collaboration |
Development of a vaccine for human influenza |
The effort is part of the Key Science-Technology Project in China(3/9) |
|
|
|
|
|
Synthetic Blood International Inc. (OTC BB:SYBD) |
Researchers at two universities |
Collaboration |
Preclinical testing on SBI's Oxycyte product |
SBI said the work could lead to development plans in cardiac bypass and valve surgery (12/17) |
|
|
|
|
|
Targeted Genetics Corp. (TGEN) |
International AIDS Vaccine Initiative and Columbus Children's Research Institute |
Collaboration |
Three-year extension of deal to support TGEN's manufacturing of clinical supply and preclinical studies to evaluate HIV antigens in a multi- component AIDS vaccine |
Targeted Genetics is expected to receive $10.7M in funding in 2004; separately, IAVI also will fund clinical trials of tgAAC09, a rAAV-based AIDS vaccine in Phase I trials; the February 2002 deal was extended through 2006 (1/8) |
|
|
|
|
|
Third Wave Technologies Inc. (TWTI) |
Armed Forces Institute of Pathology |
Purchase agreement |
Third Wave's Invader analyte-specific reagents for genetic screening |
The institute will use the system to test military personnel for genetic mutations associated with cystic fibrosis (12/9) |
|
|
|
|
|
Tm Bioscience Corp. (Canada; OTC BB: TMBIF) |
Technology Partnerships Canada |
Development agreement |
Support of Tm project to develop five genetic tests by 2006 |
TPC is contributing C$7.3M (US$5.6M) to the effort and would get royalties on resulting products, as well as Tm warrants worth C$2.5M (12/3) |
|
|
|
|
|
Vertex Pharmaceuticals Inc. (VRTX) |
Oregon Health & Science University |
Collaboration |
To discover and develop therapies aimed at various diseases |
Vertex will fund work for three years and fund a stipend for graduate researchers; as part of the deal OHSU dropped litigation against Vertex and got an exclusive license to certain Vertex patents (12/17) |
|
|
|
|
|
Vical Inc. (VICL) |
Centers for Disease Control and Prevention |
License agreement |
Vical got additional rights to commercialize a West Nile virus vaccine |
Vical is developing the vaccine, which uses its delivery technology, with an NIH unit (1/29) |
|
|
|
|
|
Vion Pharmaceuticals Inc. (VION) |
University of Innsbruck (Austria) and Austria Wirtschaftsservice Gesellschaft mbH |
Research collaboration and option agreement |
Vion will investigate cancer compounds over a 17-month option period |
Vion is paying $25,000 up front and would pay $75,000 to exercise an option for worldwide rights; it also would pay milestones and royalties (12/4) |
|
|
|
|
|
Viragen Inc. (AMEX:VRA) |
Roslin Institute (UK) |
License agreement |
The parties extended Viragen's rights to avian transgenic biomanufacturing technology |
The two-year extension continues to provide Viragen worldwide rights to commercialize the technology (3/8) |
|
|
|
|
|
Zentaris GmbH (subsidiary of AEterna Laboratories Inc.; Canada; AELA) |
University of Montpellier (France) and University of Milan (Italy) |
Development agreements |
Ghrelin antagonist compounds that could have applicability in obesity |
Zentaris will support work at the universities in exchange for exclusive worldwide rights (3/11) |
|
|
|
|
|
Zentaris GmbH (subsidiary of AEterna Laboratories Inc. Canada; AELA) |
Universities of Jena and Munster (both in Germany) |
Development agreements |
Zentaris gets access to technology in the area of proteins of the cytoskeleton, for oncology applications |
Researchers at the universities will design, screen and pharmacologically investigate compounds from the class; Zentaris will support research in exchange for exclusive rights (3/11) |
|
|
|
|
|
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
** Denotes date item ran in BioWorld International. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
